tiprankstipranks
OrthoPediatrics Corp (KIDS)
NASDAQ:KIDS
Want to see KIDS full AI Analyst Report?

OrthoPediatrics (KIDS) Price & Analysis

118 Followers

KIDS Stock Chart & Stats

$16.75
-$0.10(-0.41%)
At close: 4:00 PM EST
$16.75
-$0.10(-0.41%)

Bulls Say, Bears Say

Bulls Say
Revenue Growth & International ExpansionConsistent double-digit top-line growth and ~22% international growth diversify revenue and validate global product-market fit. Raised 2026 guidance and record patient volumes signal sustained demand, underpinning durable scale economics and greater runway for margin leverage.
Very High Gross Margins (~73%)Sustained ~73% gross margins indicate strong pricing power and favorable product economics from implant and disposable sales. High margins provide structural capacity to fund R&D and commercialization and improve profitability as operating leverage and set mix normalize.
Conservative Leverage And Liquidity BufferMeaningful cash balances and a $20M delayed-draw facility plus modest existing leverage provide financial flexibility to fund launches and commercial expansion. This buffer reduces refinancing risk while the company executes toward EBITDA and free-cash-flow breakeven.
Bears Say
Persistent GAAP LossesOngoing GAAP losses and a TTM net margin near -16% constrain internal capital formation and limit options for share-holder returns. Until GAAP profitability consistently improves, the company may need to balance growth investments against the need to demonstrate durable earnings.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow forces reliance on external capital and can slow reinvestment in sets and launches. Even with improvement, cash burn limits flexibility and raises execution risk until full-year breakeven is achieved and maintained.
Execution & Timing Risk Around Set AvailabilityRevenue recognition and higher-ASP product adoption depend on physical set supply, regulatory timing and scaled logistics. Delays or limited set availability can bottleneck revenue and delay margin improvement, making growth cadence lumpy and execution-dependent.

OrthoPediatrics News

KIDS FAQ

What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $14.42 and its highest was $23.70 in the past 12 months.
    What is OrthoPediatrics Corp’s market cap?
    OrthoPediatrics Corp’s market cap is $457.96M.
      When is OrthoPediatrics Corp’s upcoming earnings report date?
      OrthoPediatrics Corp’s upcoming earnings report date is Aug 05, 2026 which is in 53 days.
        How were OrthoPediatrics Corp’s earnings last quarter?
        OrthoPediatrics Corp released its earnings results on Apr 30, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.455 by $0.005.
          Is OrthoPediatrics Corp overvalued?
          According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does OrthoPediatrics Corp pay dividends?
            OrthoPediatrics Corp does not currently pay dividends.
            What is OrthoPediatrics Corp’s EPS estimate?
            OrthoPediatrics Corp’s EPS estimate is -0.3.
              How many shares outstanding does OrthoPediatrics Corp have?
              OrthoPediatrics Corp has 25,684,994 shares outstanding.
                What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
                OrthoPediatrics Corp reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.455. Following the earnings report the stock price went up 3.785%.
                  Which hedge fund is a major shareholder of OrthoPediatrics Corp?
                  Currently, no hedge funds are holding shares in KIDS
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    OrthoPediatrics Corp

                    OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.

                    OrthoPediatrics (KIDS) Earnings & Revenues

                    KIDS Earnings Call

                    Q1 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call conveyed strong execution and acceleration across several strategic fronts: double-digit revenue growth (13% YoY), a return to positive adjusted EBITDA, >20% OPSB growth, international acceleration, multiple promising beta launches (3P Hip, Vertiglyde) and EU MDR approvals. Management raised full-year revenue guidance and reaffirmed a path to adjusted EBITDA of ~$25M and free-cash-flow breakeven in 2026. Key short-term headwinds and risks include weather-related clinic disruptions that shifted some demand into Q2, continued GAAP/non-GAAP net losses, higher operating expense levels, lower set deployments versus prior-year (by design), and timing uncertainty around set availability and product rollouts. On balance, the strategic momentum, margin improvement and guidance raise outweigh the near-term challenges and execution/timing risks.View all KIDS earnings summaries

                    KIDS Stock 12 Month Forecast

                    Average Price Target

                    $24.63
                    ▲(47.01% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","35":"$35","19.25":"$19.25","24.5":"$24.5","29.75":"$29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,19.25,24.5,29.75,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.65,17.984615384615385,19.319230769230767,20.653846153846153,21.988461538461536,23.323076923076922,24.657692307692308,25.99230769230769,27.326923076923077,28.661538461538463,29.996153846153845,31.33076923076923,32.66538461538462,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.65,17.263461538461538,17.876923076923077,18.490384615384613,19.103846153846153,19.717307692307692,20.33076923076923,20.94423076923077,21.557692307692307,22.171153846153846,22.784615384615385,23.39807692307692,24.011538461538464,{"y":24.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.65,16.676923076923075,16.703846153846154,16.73076923076923,16.757692307692306,16.784615384615385,16.81153846153846,16.838461538461537,16.865384615384613,16.892307692307693,16.91923076923077,16.946153846153845,16.973076923076924,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.39,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.42,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.29,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Orthofix Medical
                    Tandem Diabetes Care
                    Varex Imaging
                    Bioventus
                    Treace Medical Concepts

                    Ownership Overview

                    33.38%12.67%21.93%24.45%
                    33.38% Insiders
                    21.93% Other Institutional Investors
                    24.45% Public Companies and
                    Individual Investors
                    Popular Stocks